Ajanta Pharma on Wednesday reported 4.92 per cent dip in consolidated net profit to ₹125.39 crore for the quarter ended September 2018 against a net profit of ₹131.89 crore in the year-ago period.
Consolidated revenue from operations stood at ₹544.11 crore for the reported quarter. It was ₹540.38 crore for the same period a year ago.
“This quarter has been a mixed bag for us. While the US & branded generic business in emerging market posted robust growth, India business remained flat and antimalarial business de-grew as was anticipated,” Ajanta Pharma Joint MD Rajesh Agrawal said.
Despite unfavourable market conditions in the US, the company posted robust growth for the quarter. The company’s emerging market branded generic business delivered sound performance, he added.
The company’s board has also approved payment of interim dividend of ₹9 per equity share on the face-value of ₹2 per share for the 2018-19 fiscal, Ajanta Pharma said.
Shares of Ajanta Pharma closed at Rs 1,057.75 on the BSE, up 4.67 per cent from the previous close.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.